Nov 16 (Reuters) – Pfizer Inc (PFE.N) said on Tuesday it is seeking U.S. authorization of its experimental antiviral COVID-19 pill that cut the chance of hospitalization or death for adults at risk of severe disease by 89% in a clinical trial. Pfizer said it completed submission of its application for emergency use authorization (EUA) of the …
Pfizer files for U.S. authorization of COVID-19 pill Read More »
